Preface

Senomorphics are agents that suppress or modulate the senescence-associated secretory phenotype (SASP) of senescent cells without killing them — distinct from senolytics (e.g. dasatinib + quercetin, fisetin), which selectively eliminate senescent cells.[1][2][3] The best-characterised candidate senomorphics are metformin, rapamycin (sirolimus), ruxolitinib, resveratrol and urolithin A.[4][1][3] A crucial point for point-of-care use: no senomorphic has a regulatory indication for ageing, healthspan or longevity anywhere. All such use is off-label and, for hard clinical ageing endpoints, remains experimental/expert-consensus — human evidence rests almost entirely on surrogate biomarkers and short trials, and the pivotal RCT (TAME) has not reported.[2][5][6] This summary is intended as adjunctive to, not a substitute for, conventional primary and secondary care.

1. Scope

– Covered: off-label/emerging senomorphic use in adults attending a UK longevity clinic; metformin, low-dose intermittent rapamycin/sirolimus, urolithin A, and briefly ruxolitinib/resveratrol; patient selection, baseline work-up, dosing, monitoring, safety, and practical scenarios.

– Not covered: senolytics (D+Q, fisetin, navitoclax), licensed disease-specific indications (e.g. metformin for T2DM, sirolimus for transplant/LAM), NAD⁺ precursors, and paediatrics.

– Framing: all recommendations below are adjunctive, off-label, and contingent on informed consent; several are “only in research”.

2. Background and pathophysiology

– Cellular senescence is a hallmark of ageing: senescent cells accumulate with age and, via the SASP (IL-6, IL-1α/β, CXCL chemokines, MMPs, GDF15, activin A), drive chronic sterile inflammation (“inflammaging”) and tissue dysfunction implicated in cardiometabolic, musculoskeletal, pulmonary and neurodegenerative disease.[1][7][8]

– Senomorphics target SASP-regulating signalling rather than the cells themselves — principally mTOR (rapamycin), AMPK/mitochondrial complex I (metformin), JAK/STAT (ruxolitinib), NF-κB, p38 MAPK and cGAS–STING. Urolithin A acts upstream on mitochondrial quality control by inducing PINK1/Parkin-mediated mitophagy and reducing inflammatory markers (CRP, cytokines).[4][1][2][9]

– Robust human mechanistic evidence is limited to demonstrating target engagement and biomarker modulation (e.g. weekly sirolimus 5–6 mg inhibits S6K1 phosphorylation for ≥5–7 days without mTORC2 blockade; urolithin A raises plasma levels and shifts muscle mitochondrial gene/protein expression) — not disease prevention.[10][9][11][12]

– Preclinical only (mechanistic plausibility, not human-validated): lifespan/healthspan extension by rapamycin and metformin in worms, flies, mice and non-human primates; SASP suppression by resveratrol, melatonin, rutin, dihydromyricetin; ruxolitinib alleviating frailty in aged mice. These should not be presented to patients as translatable benefits.[4][2][13]

3. Evidence base and grading

Available human evidence comprises small phase I–II RCTs, one systematic review, mechanistic/biomarker trials, and large observational cohorts (mostly in T2DM for metformin). Hard geroscience endpoints (multimorbidity, mortality, function) are essentially untested by adequately powered RCTs in healthy ageing populations.

Agent / outcome	Evidence statement	GRADE certainty	Strength of recommendation
Urolithin A → muscle endurance/mitochondrial biomarkers	RCT (n=66, 1000 mg/day 4 mo) improved muscle endurance and lowered acylcarnitines/ceramides/CRP; systematic review (5 studies, n=250) confirms dose-dependent anti-inflammatory and mitochondrial gene effects, improved strength/endurance, but no effect on physical function, ATP synthesis, or cardiovascular outcomes [11], [12]. Indirect (surrogates), imprecise, industry involvement	Moderate (biomarkers/endurance); Low (function)	Conditional — reasonable to offer as low-risk adjunct; do not promise functional/longevity benefit
Low-dose intermittent rapamycin → safety & healthspan surrogates	PEARL RCT (n≈100, 48 wk, 5–10 mg/wk): safe, no change in visceral fat; lean mass and self-reported pain improved in women at 10 mg [14]. RAPA-EX-01 (weekly 6 mg + exercise): blunted chair-stand gains vs placebo [10]. Older-adult pilots: feasible/tolerable, minor haematological changes [15]. High imprecision, inconsistency, no hard endpoints	Low	Only in research / conditional with explicit consent; no proven healthspan benefit and possible attenuation of exercise adaptation
Metformin → age-related multimorbidity/mortality in non-diabetics	Large observational data in T2DM show reduced all-cause mortality and CV events; geroprotective effect in non-diabetics is unproven — TAME and VA-IMPACT RCTs pending [3], [5]. Serious indirectness (diabetic populations), confounding	Low–Very low (non-diabetic ageing)	Only in research for longevity indication; recommend against routine use in metabolically healthy adults solely for anti-ageing
Ruxolitinib / resveratrol → ageing endpoints	Human data essentially absent for ageing; SASP effects preclinical only [2], [4]	Very low	Recommend against outside trials (ruxolitinib carries substantial toxicity)
Any senomorphic → mortality, morbidity, biological-age reversal	No adequately powered RCT with hard clinical endpoints in healthy ageing adults [5], [6]	Very low	Only in research

Overall: do not infer clinical benefit from favourable biomarker or surrogate changes — the biomarker-to-outcome linkage is not established for any senomorphic.[16][8][6]

4. Patient selection and indications

– Who might reasonably be considered (adjunctive, consented):

– Urolithin A: middle-aged/older adults with age-related decline in muscle endurance or low physical performance (e.g. 6-min walk ≤550 m), or seeking a low-risk mitochondrial-support adjunct — best-supported and safest option.[9][11][12]

– Metformin: adults with overweight/obesity, prediabetes, insulin resistance or high cardiometabolic risk — here use aligns with a recognised (if off-label for “ageing”) metabolic rationale.[5][3]

– Rapamycin/sirolimus: highly selected, well-informed adults accepting experimental status, ideally within a trial/registry framework.[14][6]

– Exclusion / high-risk groups (avoid or specialist input only):

– Rapamycin: immunosuppression risk — avoid with active/recurrent infection, poor wound healing, planned surgery, live vaccination, uncontrolled dyslipidaemia/diabetes, pregnancy/conception plans (impairs spermatogenesis, disrupts menses), interstitial lung disease.[6]

– Metformin: eGFR <30 (contraindicated), caution eGFR 30–45; risk of lactic acidosis with hepatic impairment, tissue hypoxia, decompensated heart failure, alcohol excess; withhold around iodinated contrast/acute illness (per MHRA/BNF labelling).

– Frailty/sarcopenia: caution — chronic mTOR inhibition and even metformin may blunt anabolic/exercise responses.[10]

– Regulatory/ethical status: all off-label for longevity. Best practice is use within a clinical-trial or registry framework, or as adjunctive care with documented informed consent explicitly stating experimental status and absence of hard-endpoint data.

5. Assessment and baseline work-up

– History/exam: full medication review (drug interactions), comorbidities, infection/surgical history, fertility/pregnancy plans, alcohol, vaccination status; frailty screen (e.g. gait speed, grip strength, chair-stand), functional baseline (6-min walk where relevant).

– Baseline investigations: FBC, U&E/eGFR, LFTs, fasting glucose/HbA1c, fasting lipids, hs-CRP; for metformin also B12; for rapamycin baseline lipids, glucose and FBC are essential given metabolic and haematological effects.[14][15][6]

– Optional biomarkers (research/monitoring, not decision-making): SASP/inflammatory panel (IL-6, GDF15, activin A), p16^INK4a in peripheral T cells, or epigenetic clocks — regard as exploratory gerodiagnostics; changes must not be over-interpreted as clinical benefit.[16][8][17]

– Risk stratification: stratify separately for likely benefit (functional/metabolic deficit present) and harm (renal/hepatic function, infection/wound risk, frailty, polypharmacy). Metabolically healthy, robust adults gain least and should generally be steered to lifestyle measures and trials.

6. Dosing regimens and practical implementation

– Regimens supported by the best (still limited) human data:

– Urolithin A: 500–1000 mg once daily orally; RCT efficacy on endurance at 1000 mg/day over 4 months; well tolerated; bioavailable 250–2000 mg (t½ ~17–22 h).[9][11][12]

– Metformin (off-label longevity, in metabolic-risk patients): standard escalating dosing (e.g. 500 mg with evening meal, titrated to 1500–2000 mg/day or MR equivalent) to limit GI effects; individualise to renal function.[5][3]

– Regimens extrapolated from early-phase data — use with caution / research setting:

– Rapamycin/sirolimus: intermittent weekly dosing (5–10 mg once weekly) used in PEARL and ~6 mg/week in sirolimus trials, chosen to inhibit mTORC1 while sparing mTORC2 and reducing metabolic toxicity; chronic daily dosing should be avoided for longevity purposes owing to glucose intolerance, dyslipidaemia and immunosuppression. Optimal dose/cadence is unknown, and weekly dosing may blunt exercise gains.[10][14][18]

– Ruxolitinib, resveratrol: no validated longevity regimen — do not prescribe for this indication.[4][2]

– Non-pharmacological adjunct: structured resistance and aerobic exercise remains the intervention with the strongest functional evidence and should anchor any regimen; note the possible pharmacodynamic conflict between weekly rapamycin and exercise adaptation.[10]

The relative dose-dependence of mTOR-inhibitor toxicity (chronic/high-dose harmful; intermittent/low-dose safer) is summarised below.

Figure 3 The known and unknown effects of rapalog-dosing regimens on metabolic health, the immune system, healthspan and longevity in humans and mice. Chronic (daily) dosing of rapamycin is associated with impaired blood glucose regulation and hyperlipidemia in humans and mice, while everolimus in mice has somewhat reduced effects on glucose homeostasis. Intermittent or low-dose regimens of rapamycin or everolimus are associated with reduced side effects, while the mTORC1-selective rapalog DL001 does not impair blood glucose control or alter circulating lipid levels. Blue up arrow, improvement; red down arrow, impairment; dash indicates no change; question mark indicates unknown.

7. Monitoring, safety and follow-up

– Monitoring plan:

– Rapamycin: FBC (anaemia, cytopenias — pilot data show falls in Hb/Hct/RBC indices), fasting glucose/HbA1c, fasting lipids; clinical surveillance for infections, mouth ulcers/stomatitis, oedema, impaired wound healing, rash.[15][6]

– Metformin: renal function (at least annually, more often if eGFR 30–45), B12 periodically, GI tolerance; counsel on withholding during acute illness/contrast.

– Urolithin A: minimal — clinical tolerance; LFTs if clinically indicated; adverse events in trials were mild/moderate and generally unrelated.[12]

– Ageing biomarkers (hs-CRP, SASP panel, epigenetic age) may be tracked for research but should not drive dose changes.[16][8]

– Suggested intervals: baseline → 6 weeks (early tolerability/bloods for rapamycin/metformin) → 3 months → 6–12 monthly thereafter, with functional reassessment (e.g. chair-stand, grip, 6-min walk) at 3–6 months.

– Adverse effects:

– Rapamycin (dose-dependent): common — stomatitis/mouth ulcers, rash, GI upset, mild cytopenias; with chronic/higher dosing — hyperglycaemia/new-onset diabetes, hypercholesterolaemia, hypertriglyceridaemia, immunosuppression with serious infection risk, impaired wound healing, gonadal dysfunction/impaired spermatogenesis, menstrual disruption. Actions: withhold before surgery/infection; stop for significant cytopenia, uncontrolled hyperglycaemia/dyslipidaemia or serious infection; refer as needed.[18][6]

– Metformin: GI intolerance (common), B12 deficiency (long-term); rare but serious lactic acidosis in renal/hepatic impairment or hypoxic states.

– Urolithin A: mild GI symptoms; no serious signal to date.[12]

– Interactions: rapamycin (sirolimus) is a CYP3A4/P-gp substrate — major interactions with azoles, macrolides, grapefruit, some statins (myopathy risk), calcineurin inhibitors; metformin — additive lactic-acidosis risk with alcohol and nephrotoxins; combined metformin + rapamycin is proposed specifically to offset rapamycin-induced insulin resistance but remains investigational.[18]

– Special populations: avoid all in pregnancy/breastfeeding (rapamycin contraindicated; urolithin/metformin — insufficient safety data for longevity use). Renal impairment — metformin dose-limited/contraindicated by eGFR. Hepatic impairment — caution with all. Frailty/extremes of age — favour urolithin A and exercise; use rapamycin only with specialist oversight.

8. Contraindications and cautions

– Absolute: pregnancy/planned conception (rapamycin); active serious infection or perioperative period (rapamycin); eGFR <30 (metformin); known hypersensitivity.

– Relative / specialist advice: frailty and active resistance-training programmes (rapamycin may blunt adaptation); uncontrolled diabetes or dyslipidaemia (rapamycin); eGFR 30–45, hepatic impairment, high alcohol intake (metformin); significant polypharmacy with CYP3A4/P-gp interactions (rapamycin).[10]

– Harm likely > benefit with current evidence: routine rapamycin or metformin in metabolically healthy, robust adults for anti-ageing alone; any ruxolitinib use for longevity.

9. Practical management scenarios

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors (e.g. central obesity, prediabetes, raised hs-CRP).

– Recommendation: Consider metformin as an adjunct (Conditional) — rationale grounded in metabolic risk, not proven longevity benefit; offer urolithin A as a low-risk mitochondrial adjunct if functional/muscle concerns (Conditional).[5][3][11][12]

– Steps: (1) Assess renal/hepatic function, HbA1c, lipids, B12. (2) Consent: explicitly off-label for ageing; anchor on lifestyle. (3) Initiate metformin 500 mg evening, titrate to tolerance; ± urolithin A 500–1000 mg/day. (4) Review at 6 weeks/3 months (GI tolerance, renal function, HbA1c). (5) Stop if intolerance, eGFR falls <30, or no metabolic benefit; refer if diabetes/CVD emerges.

Scenario B — Older, frail patient with multimorbidity.

– Recommendation: Avoid rapamycin (immunosuppression, wound-healing, possible blunted exercise adaptation); Consider urolithin A + supervised exercise as the safest functional adjunct (Conditional); metformin only if a metabolic indication and adequate renal function.[10][6][11][12]

– Steps: (1) Frailty and function assessment, medication reconciliation, renal function. (2) Consent with realistic expectations. (3) Prioritise resistance/aerobic exercise ± urolithin A 1000 mg/day. (4) Reassess function (grip, gait, chair-stand) at 3 months. (5) Escalate/refer for falls, weight loss or functional decline.

Scenario C — Patient already under specialist care wanting a senomorphic adjunct.

– Recommendation: Restrict to research/registry or defer to the treating specialist (Conditional/Only in research) — interaction and immunosuppression risks are highest here.[18][6]

– Steps: (1) Review the specialist regimen for CYP3A4/P-gp and immunosuppression interactions. (2) Liaise with and obtain agreement from the specialist team; document. (3) If proceeding, favour urolithin A (lowest interaction risk). (4) Shared monitoring plan. (5) Stop for any interaction, infection or specialist concern.

10. Research gaps and future directions

– Hard clinical endpoints: no completed RCT shows senomorphics reduce mortality, multimorbidity or reverse biological ageing in healthy adults — TAME (metformin) and VA-IMPACT are pivotal and awaited.[5][3]

– Rapamycin dose/cadence: optimal intermittent regimen, interaction with exercise, and long-term safety in non-transplant populations remain unresolved.[10][6]

– Biomarkers: no validated, regulator-accepted “gerodiagnostic” links senomorphic-induced biomarker change to clinical outcome — SASP panels, p16, and epigenetic clocks need prospective validation before guiding therapy.[16][8][17]

– Urolithin A: longer trials across multiple organ systems and on clinical function (not just endurance/biomarkers) are needed.[12]

– Populations and combinations: frail, female-specific, and metformin+rapamycin combination data are sparse.[14][18]

– Practice statement: outside clear metabolic indications, senomorphic use for longevity should ideally occur within well-designed trials or structured registries with informed consent, not as routine care.

References

1. Senomorphic Agents: Multi-Target Strategies to Tame the Senescence-Associated Secretory Phenotype for Healthy Ageing. Kong Y, Zhang Q, Zhang J, Fu Q. Experimental Gerontology. 2026;223:113249. doi:10.1016/j.exger.2026.113249.
2. Cellular Senescence, Inflammaging and Cardiovascular Disease. Zanders L, Arifaj D, Wagner JUG, Dimmeler S. Immunological Reviews. 2026;337(1):e70084. doi:10.1111/imr.70084.
3. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
4. Cellular senescence: the good, the bad and the unknown. Huang W, Hickson LJ, Eirin A, Kirkland JL, Lerman LO. Nature Reviews. Nephrology. 2022;18(10):611-627. doi:10.1038/s41581-022-00601-z.
5. Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop. Espinoza SE, Khosla S, Baur JA, de Cabo R, Musi N. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(Suppl 1):53-60. doi:10.1093/gerona/glad034.
6. Biomarkers of aging: from molecules and surrogates to physiology and function. Furrer R, Handschin C. Physiological Reviews. 2025;105(3):1609-1694. doi:10.1152/physrev.00045.2024.
7. Senolytics and Senomorphics: Natural and Synthetic Therapeutics in the Treatment of Aging and Chronic Diseases. Lagoumtzi SM, Chondrogianni N. Free Radical Biology & Medicine. 2021;171:169-190. doi:10.1016/j.freeradbiomed.2021.05.003.
8. A Compendium of Circulating Biomarkers of Senescence in Humans: Insights on Mechanistic Impact Across Health Domains and Modulation by Therapeutic Interventions. Olinger B, Basisty N. Ageing Research Reviews. 2026;121:103254. doi:10.1016/j.arr.2026.103254.
9. Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function During Ageing. Broome SC, Whitfield J, Karagounis LG, Hawley JA. Sports Medicine (Auckland, N.Z.). 2024;54(9):2291-2309. doi:10.1007/s40279-024-02072-7.
10. Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial. Stanfield B, Leroux B, Kaeberlein M, Jones J, Lucas R. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(2):e70274. doi:10.1002/jcsm.70274.
11. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. Liu S, D’Amico D, Shankland E, et al. JAMA Network Open. 2022;5(1):e2144279. doi:10.1001/jamanetworkopen.2021.44279.
12. Targeting Aging With Urolithin a in Humans: A Systematic Review. Kuerec AH, Lim XK, Khoo AL, et al. Ageing Research Reviews. 2024;100:102406. doi:10.1016/j.arr.2024.102406.
13. The natural flavonoid dihydromyricetin targets senescent cells via PRDX2 and alleviates age-related diseases. Xu Q, Li G, Zhang H, et al. Nature Communications. 2026;17(1):3936. doi:10.1038/s41467-026-70302-9.
14. Influence of Rapamycin on Safety and Healthspan Metrics After One Year: PEARL Trial Results. Moel M, Harinath G, Lee V, et al. Aging. 2025;17(4):908-936. doi:10.18632/aging.206235.
15. A Randomized Control Trial to Establish the Feasibility and Safety of Rapamycin Treatment in an Older Human Cohort: Immunological, Physical Performance, and Cognitive Effects. Kraig E, Linehan LA, Liang H, et al. Experimental Gerontology. 2018;105:53-69. doi:10.1016/j.exger.2017.12.026.
16. Cellular senescence and senolytics: the path to the clinic. Chaib S, Tchkonia T, Kirkland JL. Nature Medicine. 2022;28(8):1556-1568. doi:10.1038/s41591-022-01923-y.
17. Therapeutic targeting of senescent cells in the CNS. Riessland M, Ximerakis M, Jarjour AA, Zhang B, Orr ME. Nature Reviews. Drug Discovery. 2024;23(11):817-837. doi:10.1038/s41573-024-01033-z.
18. mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?. Kezic A, Popovic L, Lalic K. Oxidative Medicine and Cellular Longevity. 2018;2018:2640342. doi:10.1155/2018/2640342.
19. Targeting the biology of aging with mTOR inhibitors. Mannick JB, Lamming DW. Nature Aging. 2023;3(6):642-660. doi:10.1038/s43587-023-00416-y.